13.05
price up icon11.88%   1.525
 
loading
Schlusskurs vom Vortag:
$11.53
Offen:
$11.54
24-Stunden-Volumen:
290.65K
Relative Volume:
0.72
Marktkapitalisierung:
$700.39M
Einnahmen:
$2.22M
Nettoeinkommen (Verlust:
$-40.51M
KGV:
-10.16
EPS:
-1.2847
Netto-Cashflow:
$-46.53M
1W Leistung:
+16.85%
1M Leistung:
+13.26%
6M Leistung:
+24.16%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$11.44
$13.02
1-Wochen-Bereich:
Value
$10.54
$12.91
52-Wochen-Spanne:
Value
$5.14
$29.46

Upstream Bio Inc Stock (UPB) Company Profile

Name
Firmenname
Upstream Bio Inc
Name
Telefon
781-208-2466
Name
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
UPB's Discussions on Twitter

Vergleichen Sie UPB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
UPB
Upstream Bio Inc
13.02 578.28M 2.22M -40.51M -46.53M -1.2847
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.50 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.19 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Upstream Bio Inc Stock (UPB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-05 Eingeleitet JP Morgan Overweight
2024-11-05 Eingeleitet Piper Sandler Overweight
2024-11-05 Eingeleitet TD Cowen Buy
2024-11-05 Eingeleitet William Blair Outperform

Upstream Bio Inc Aktie (UPB) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Upstream Bio Inc. stock priceFree Market Dynamics Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Upstream Bio Inc. Stock Analysis and ForecastHigh-performance investment picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛

Jul 19, 2025
pulisher
Jul 18, 2025

how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest

Jul 18, 2025
pulisher
Jul 17, 2025

What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser

Jul 17, 2025
pulisher
Jul 15, 2025

Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Upstream Bio management to meet with Piper Sandler - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews

Jul 09, 2025
pulisher
Jul 08, 2025

Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan

Jul 08, 2025
pulisher
Jun 30, 2025

Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 27, 2025
pulisher
Jun 19, 2025

Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest

Jun 19, 2025
pulisher
Jun 16, 2025

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks

Jun 16, 2025
pulisher
Jun 15, 2025

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable

Jun 15, 2025
pulisher
Jun 15, 2025

Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times

Jun 15, 2025
pulisher
Jun 15, 2025

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025
pulisher
Jun 08, 2025

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Upstream Bio to Present Mechanistic Insights into - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan

Jun 04, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 02, 2025

Finanzdaten der Upstream Bio Inc-Aktie (UPB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Upstream Bio Inc-Aktie (UPB) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
ORBIMED ADVISORS LLC
Director
Oct 15 '24
Buy
17.00
825,000
14,025,000
4,554,873
AI Upstream LLC
10% Owner
Oct 15 '24
Buy
17.00
1,175,000
19,975,000
1,175,000
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$113.95
price down icon 0.57%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):